Towards Internationalization, Global Expansion3D Global Biotech, founded in December 2014, originated from Taipei Medical University's "Biomedical Equipment R&D and Product Prototyping Center." With a 5 billion capital injection from the Diamond Fund, we set out as a new-generation biotech company with the goal of developing medical materials for human reconstruction. 3D Global Biotech employs cell culture systems, 3D printing technology, and a foundation of "bio-inks" hydrogel to target the production of customized autologous cell medical products. Currently, we have conducted various tests with entities both domestically and internationally, actively advocating for the establishment of relevant domestic regulations. We hope that 3D bioprinting has the opportunity to become a sophisticated cutting-edge industry for Taiwan on the international stage. |
 |
 |
Social Responsibility3D Global Biotech has developed a platform for human organ bioprinting technology and composite bio-inks. By printing various cells, we achieve tissue and organ reconstruction. In alignment with domestic government policies, we have formed interdisciplinary alliances with top medical centers, renowned research institutions, international enterprises, and distribution partners both domestically and abroad—bridging production, government, academia, research, and medical sectors. Our aim is to create a global frontier in biotech, positioning Three Ding Biotech as a leading expert in the specialized field of biological 3D printing globally, anchored in Taiwan but with a global perspective. |
 |